Skip to main content

Latest stock market podcasts

From the helm: Opthea Ltd (ASX:OPT) Chief Executive Officer, Fred Guerard

Bell Direct
February 7, 2025

In this latest instalment of Bell Direct’s From the helm series, we kick off 2025 with an exciting deep dive into the healthcare sector. Host Bell Direct’s Market Analyst, Grady Wulff sits down with Opthea (ASX:OPT) CEO, Fred Guerard to discuss the company’s remarkable 168% share price surge over the past six months as it advances toward commercialising its novel retinal disease treatment, Sozinibercept. With an initial focus on wet age-related macular degeneration, Opthea is poised to disrupt the market with its innovative approach to vision care.

In this video, Fred discusses:

  • (0:43): Opthea’s history and its mission in the healthcare space
  • (1:40): how Sozinibercept compares to existing therapies
  • (3:22): recent Phase 3 data and confidence in trial success
  • (6:22): commercialisation strategy and financial runway
  • (8:15): key milestones and future pipeline treatments.

Note: This interview was filmed on 5 February 2025.

Weekly Wrap 21 March

Bell Direct
March 21, 2025

Morning Bell 20 March

Bell Direct
March 20, 2025

Morning Bell 19 March

Bell Direct
March 19, 2025

Morning Bell 18 March

Bell Direct
March 18, 2025

Morning Bell 17 March

Bell Direct
March 17, 2025

Weekly Wrap 14 March

Bell Direct
March 14, 2025

Morning Bell 13 March

Bell Direct
March 13, 2025

Morning Bell 12 March

Bell Direct
March 12, 2025

Morning Bell 11 March

Bell Direct
March 11, 2025

Morning Bell 10 March

Bell Direct
March 10, 2025

Weekly Wrap 7 March

Bell Direct
March 7, 2025